Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Cancer Mechanisms and Therapy
TopicLeading institutions, researchers & key papers
This cluster of papers focuses on the role of Pim oncogenes, particularly Pim-1 and Pim-2 kinases, in promoting tumorigenesis, cancer progression, and metastasis. The cluster also explores the potential of targeting Pim kinases as a therapeutic approach, with a specific emphasis on their involvement in cell survival pathways, phosphorylation of key proteins, and their association with hematological malignancies.
179
Works
IDs:OpenAlex
How has Cancer Mechanisms and Therapy's publication output changed over time?
ScholarIQpublication output · 1997–2021
Output grew100% over the shown period — from 1 works in 1997 to 2 in 2021.
1
1
1
2
2
3
1
1
1
2
1997200320102012201320142015201820202021
What are the most-cited papers on Cancer Mechanisms and Therapy?
ScholarIQmost cited works
EGFR activation limits the response of liver cancer to lenvatinib
Haojie Jin, Yao Shi, Yuanyuan Lv, Shengxian Yuan, Christel Ramirez, Cor Lieftink, Liqin Wang, Siying Wang, Cun Wang, Matheus Henrique Dias, Fleur Jochems, Yuan Yang, Astrid Bosma, E. Marielle Hijmans, Marnix H. P. de Groot, Serena Vegna, Dan Cui, Yangyang Zhou, Ling Jing, Hui Wang, Yuchen Guo, Xingling Zheng, Nikita Isima, Hai-Qiu Wu, Chong Sun, Roderick L. Beijersbergen, Leila Akkari, Weiping Zhou, Bo Zhai, Wenxin Qin, René Bernards
Nature. 2021440 Citations
Direct Interaction of the Rho GDP Dissociation Inhibitor with Ezrin/Radixin/Moesin Initiates the Activation of the Rho Small G Protein
Kazuo Takahashi, Takuya Sasaki, Akiko Mammoto, Kenji Takaishi, Takaaki Kameyama, Sachiko Tsukita, Shöichiro Tsukita, Yoshimi Takai
S140251998. 1997429 CitationsOPEN ACCESS
Exome sequencing of hepatitis B virus–associated hepatocellular carcinoma
Jian Huang, Qing Deng, Qun Wang, Kun Yu Li, Ji Hong Dai, Li Niu, Zhi Dong Zhu, Bo Zhou, Xiao Yan Liu, Rui Fang Liu, Qian Lan Fei, Hui Chen, Bing Cai, Boping Zhou, Hua-Sheng Xiao, Lun Qin, Ze‐Guang Han
S137905309. 2012393 Citations
Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations
Masao Mizuki, Joachim Schwäble, Claudia Steur, Chunaram Choudhary, Shuchi Agrawal, Bülent Sargin, Björn Steffen, Itaru Matsumura, Yuzuru Kanakura, Frank D. Böhmer, Carsten Müller‐Tidow, Wolfgang E. Berdel, Hubert Serve
Blood. 2003298 CitationsOPEN ACCESS
LINC01638 lncRNA activates MTDH-Twist1 signaling by preventing SPOP-mediated c-Myc degradation in triple-negative breast cancer
Liyun Luo, Hailin Tang, Ling Li, Nan Li, Xiaoting Jia, Zhijie Zhang, Xiaorong Wang, Lejuan Shi, Jiang Yin, Ni Qiu, Hao Liu, Ying Song, Kai Luo, Hongsheng Li, Zhimin He, Guopei Zheng, Xiaoming Xie
S128439998. 2018151 Citations
Where is Cancer Mechanisms and Therapy research published, and who funds it?
ScholarIQvenues & funding sources
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Cancer Mechanisms and Therapy is open access?
ScholarIQopen access share
47%OPEN ACCESS
Gold
13%
Green
7%
Hybrid
20%
Bronze
7%
Closed
53%
Related on ScholarIQ
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
Paper
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Paper
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
Paper
<i>MET</i> amplification occurs with or without <i>T790M</i> mutations in <i>EGFR</i> mutant lung tumors with acquired resistance to gefitinib or erlotinib
Paper
BRAF mutation predicts sensitivity to MEK inhibition
Paper
Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling
Paper